Haleon (HLN) Earnings Date & Reports
Haleon is one of the largest consumer health companies in the world... Show more
HLN is expected to report earnings to rise 1.11% to 12 cents per share on July 30
Haleon plc (HLN) Q1 2026 Trading Statement Earnings Recap: North America Returns to Growth
Key Takeaways
- Haleon reported Q1 organic revenue growth of 2.2%, driven by strong Oral Health performance up 8.3%.
- Total reported revenue reached £2,857 million, a 0.1% increase from £2,853 million in Q1 2025.
- Weak cold and flu season impacted growth by approximately 130 basis points (1.3 percentage points).
- Company reaffirmed FY 2026 guidance for 3-5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency.
- Progress on £500 million share buyback program, with about 36% completed.
- Expect growth acceleration through the remainder of 2026.
Earnings Context and Why It Matters
Haleon plc, a leading consumer health company with powerhouse brands like Sensodyne, Centrum, and Panadol, continues to navigate post-spin-off challenges from its 2022 separation from GSK. Following FY 2025 organic revenue growth of 3.0%, investors closely monitor Q1 Trading Statements for signs of sustained momentum amid macroeconomic headwinds and seasonal factors. This update is pivotal as it signals recovery in key markets like North America and validates strategic priorities such as innovation and productivity. For shareholders, it underscores Haleon's ability to deliver in a competitive landscape, where category leaders gain share through targeted investments, influencing stock valuation and confidence in medium-term 4-6% annual organic growth targets.
In its Q1 2026 Trading Statement for the three months ended March 31, 2026, Haleon posted reported revenue of £2,857 million, up 0.1% year-over-year from £2,853 million, aligning closely with analyst expectations around £2.86 billion. Organic revenue growth (at constant currency, excluding divestments and other items) came in at 2.2%, below Q1 2025's 3.5% but meeting consensus forecasts amid a weak cold and flu season. This reflected 2.4% price growth offset by a 0.2% volume/mix decline.
Geographically, North America returned to 1.0% organic growth (£932 million revenue), EMEA & LatAm grew 2.1% (£1,240 million), and APAC expanded 4.0% (£685 million). By category, Oral Health excelled at 8.3% organic growth (£932 million), fueled by double-digit gains in Sensodyne and parodontax. Vitamins, Minerals, and Supplements (VMS) rose 1.7%, while Respiratory Health fell 3.4% due to seasonal weakness. Pain Relief, Digestive Health, and Therapeutic Skin Health showed mixed results, largely flat to modestly positive.
No earnings per share (EPS) or full profit figures were disclosed in this trading update, consistent with Haleon's format for Q1. FY 2026 guidance was reaffirmed, with supply chain productivity supporting gross margin expansion.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock analysis workflow.
Market Reaction and Investor Sentiment
HLN shares rose about 1% following the April 29 release, reflecting positive investor reception to North America's growth return and reaffirmed guidance despite seasonal drags. Sentiment remains constructive, with focus on Oral Health strength and productivity gains offsetting weak Respiratory Health. Analysts noted the results met expectations, supporting confidence in full-year delivery amid global uncertainties.
Forward Outlook and Key Factors to Monitor
Haleon anticipates organic revenue growth acceleration in H2 2026 to meet its 3-5% full-year target, backed by high-single-digit adjusted operating profit expansion at constant currency. Investors should watch progress on supply chain productivity, which is driving gross margin improvements through cost efficiencies.
Key upcoming catalysts include the H1 2026 results on July 30 and Q3 Trading Statement in late October. Strategic operating model changes announced in January aim to boost agility and growth, particularly in innovation rollouts like Sensodyne Clinical and Centrum activations. Share buybacks continue, with £500 million allocated for the year.
Broader dynamics to track: cold and flu season normalization, North American momentum amid consumer spending pressures, and emerging market resilience (4.3% Q1 growth). Macro factors like FX (expected neutral) and geopolitical tensions could influence performance. Medium-term guidance of 4-6% organic revenue growth remains unchanged, emphasizing sustained category leadership.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
Industry PharmaceuticalsGeneric